300529 Jafron Biomedical
- 27.61
- -0.53-1.88%
Jafron Biomedical News
Jafron Biomedical Co.,Ltd. (SZSE:300529) Pays A CN¥0.40 Dividend In Just Three Days
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Jafron Biomedical Co.,Ltd. (SZSE:300529) is about to go ex-d
Jianfan Biotech (300529.SZ) plans to pay 4 yuan for 10 shares to be deducted from interest on May 31
Zhitong Finance App News, Jianfan Biotech (300529.SZ) announced that the company's 2023 equity distribution plan: 4 yuan (tax included) for every 10 shares to all shareholders; the exclusion date is: May 31, 2024.
Is Jafron BiomedicalLtd (SZSE:300529) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
There May Be Reason For Hope In Jafron BiomedicalLtd's (SZSE:300529) Disappointing Earnings
Jafron Biomedical Co.,Ltd.'s (SZSE:300529) stock was strong despite it releasing a soft earnings report last week. However, we think the company is showing some signs that things are more promising t
Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is On The Mark
With a price-to-earnings (or "P/E") ratio of 42.3x Jafron Biomedical Co.,Ltd. (SZSE:300529) may be sending bearish signals at the moment, given that almost half of all companies in China have P/E rati
Jianfan Biotech (300529.SZ): Net profit of 285 million yuan in the first quarter increased by 44.90% year-on-year
Gelonghui, April 25, 丨 Jianfan Biotech (300529.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 744 million yuan, up 30.00% year on year; net profit attributable to shareholders of listed companies was 285 million yuan, up 44.90% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 271 million yuan, up 42.74% year on year; basic earnings per share were 0.3512 yuan.
The Recent 12% Gain Must Have Brightened CEO Fan Dong's Week, Jafron Biomedical Co.,Ltd.'s (SZSE:300529) Most Bullish Insider
Key Insights Significant insider control over Jafron BiomedicalLtd implies vested interests in company growth The top 4 shareholders own 51% of the company Ownership research along with analyst f
Jianfan Biotech (300529.SZ) spent about 500 million yuan to complete the repurchase of 3% shares
Jianfan Biotech (300529.SZ) issued an announcement. As of April 3, 2024, the company has approved a special repurchase certificate...
Jianfan Biotech (300529.SZ): It has production bases in Zhuhai, Beijing, Tianjin, Hubei and other places
Gelonghui March 15 丨 Jianfan Biotech (300529.SZ) said on the investor interactive platform that the company has production bases in Zhuhai, Beijing, Tianjin, Hubei and other places.
Jafron BiomedicalLtd's (SZSE:300529) Earnings Trajectory Could Turn Positive as the Stock Increases 7.1% This Past Week
Jafron Biomedical Co.,Ltd. (SZSE:300529) shareholders should be happy to see the share price up 14% in the last month. But that is small recompense for the exasperating returns over three years. I
Jianfan Biology (300529.SZ): Participated in volume procurement of hemodialysis medical consumables by the Interprovincial Alliance
On March 14, Gelonghui Biotech (300529.SZ) announced that the company and its wholly-owned subsidiary Zhuhai Jianfan Blood Purification Technology Co., Ltd. (“Jianfan Blood Purification”) participated in the volume procurement bidding process of the Henan Interprovincial Hemodialysis Medical Consumables Alliance. According to the “Interprovincial Alliance Procurement Notice for Hemodialysis Medical Consumables (7)” recently issued by the Henan Provincial Medical Security Bureau, the company and Jianfan Blood Purification selected high-throughput hemodialysis devices, non-high-throughput hemodialysis devices, and hemodialysis pipeline products for this centralized procurement.
Jianfan Biology (300529.SZ): Currently, the company's channel inventory situation is at a healthy level
Gelonghui March 12 丨 Jianfan Biotech (300529.SZ) was surveyed by a specific target on March 8, 2024, and asked “the current channel inventory situation?” The company replied that qualitatively speaking, the company's channel inventory situation is currently at a healthy level.
Jianfan Biology (300529.SZ): Up to now, nephrology products have covered more than 6,000 hospitals, and hepatology products have covered more than 2,000 hospitals
Gelonghui March 12 丨 Jianfan Biotech (300529.SZ) was surveyed by specific subjects on March 8, 2024, on “What is the hospital coverage of the company's products?” The company replied that up to now, nephrology products have covered more than 6,000 hospitals, and hospitals that can perform dialysis treatment have basically been covered. Hepatology products cover more than 2,000 hospitals, and critical care products cover more than 1,600 hospitals (hepatology and critical care are mainly in tertiary hospitals). Next, the company will focus on improving clinical use in hospitals already covered.
Jianfan Biotech (300529.SZ) has repurchased 2.18% of shares at a cost of 342 million yuan
Jianfan Biotech (300529.SZ) announced that as of February 29, 2024, the company is using centralized bidding transactions...
Jafron Biomedical Co.,Ltd.'s (SZSE:300529) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
It is hard to get excited after looking at Jafron BiomedicalLtd's (SZSE:300529) recent performance, when its stock has declined 12% over the past three months. But if you pay close attention, you mi
Jafron BiomedicalLtd (SZSE:300529) Is Reinvesting At Lower Rates Of Return
There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that, an expand
Jianfan Biotech (300529.SZ) has obtained EU MDR certification for some products
Jianfan Biotech (300529.SZ) issued an announcement. The company recently received a notice from the EU Notified Body. The company's product 1...
Jianfan Biotech (300529.SZ) has repurchased 2.13% of shares at a cost of 336 million yuan
Jianfan Biotech (300529.SZ) announced that as of January 31, 2024, the company will use centralized bidding transactions...
Jianfan Biotech (300529.SZ) has repurchased a total of 1.01% of its shares at a cost of 172 million yuan
Jianfan Biotech (300529.SZ) announced that as of January 23, 2024, the company is using centralized bidding transactions...
What You Can Learn From Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E
Jafron Biomedical Co.,Ltd.'s (SZSE:300529) price-to-earnings (or "P/E") ratio of 35.1x might make it look like a sell right now compared to the market in China, where around half of the companies hav
Analysis
Price Target
No Data
